US stuck in a 'horrible plateau' of COVID-19 deaths, experts say
“The pace of COVID-19 deaths has remained relatively steady since May, despite an uptick in July to about 400 a day, according to a USA TODAY analysis of Johns Hopkins University data.” - Adrianna Rodriguez
As reports of ‘Paxlovid rebound’ increase, Covid researchers scramble for answers
“As he was treating some of the nation’s first coronavirus patients, Andre Kalil noticed something unusual about the new virus: Patients didn’t always progress linearly. They’d get better, then worse. Then sometimes better again.” - Jason Mast
The 'worst variant' is here
“Nearly two-and-a-half years since the coronavirus pandemic began, the most infectious and transmissible variant yet has arrived.” - Eliza Mackintosh
Coronavirus 'running freely' across the globe, WHO warns
“The World Health Organization is urging governments around the world to ramp up surveillance, testing and vaccine deployment as omicron subvariants drive a rise in COVID-19 cases and hospitalizations.” - Erica Carbajal
New Covid subvariants BA.4 and BA.5 are the most contagious yet – and driving Australia’s third Omicron wave
“Australia is heading for its third Omicron wave in the coming weeks, as BA.4 and BA.5 become the dominant Covid strains.” - Adrian Esterman
CovInnovations Appoints Jamie Jones as Chief Executive Officer
CovInnovations, a clinical-stage targeted COVID-19 therapeutic, diagnostic, and assessment company, today announced the appointment of Jamie Jones as Chief Executive Officer (CEO).
You Are Going to Get COVID Again … And Again … And Again
“Will the danger mount each time, or will it fade away?” - Katherine J. Wu
CovInnovations™ Announces Partnership with Roseman University for COVID-19 Treatment and Therapy Research
Preliminary data for new late-stage treatment shows at least 93.5 percent survival rate for patients who are oxygen dependent or intubated.
New COVID Wave Could Infect 100M People, Officials Say
FDA finds ‘no evidence’ that second Pfizer pill stops repeat COVID-19 symptoms
“While Pfizer’s COVID-19 antiviral Paxlovid does offer a reduction in hospitalization and deaths, there is currently “no evidence” to suggest that prolonging and repeating a course of the drug has any more benefit, according to an FDA official.” - Joseph Choi
Covinnovations™ Seeks $25m For COVID-19 Treatments
Covinnovations™, a Las Vegas-based developer of later-stage COVID-19 treatments, is looking to raise USD 25m, interim CEO Kristine Leavitt told Mergermarket during the Biotech Showcase Conference.
Covinnovations™ to Present to Investors at 2022 Biotech Showcase
LAS VEGAS – Covinnovations™ has been invited to participate in the 2022 Biotech Showcase, an investor conference for innovators in medical, life sciences and other biotechnology industries, January 10-12, 2022. Covinnovations™ will highlight a revolutionary new treatment, CovArrest™, for hospitalized patients with severe COVID-19 symptoms. An earlier version of the drug significantly reduced hospital length …
Covinnovations™ Announces Plans for FDA EUA for CovArrest™
Covinnovations™ announced Friday that it has begun the process for FDA Emergency Use Authorization (EUA) for its CovArrest™ COVID-19 treatment. CovArrest™ is a patent-pending, trademarked drug combination, created by founder and inventor, Dr. Aury Nagy. It halts the cytokine storm that COVID-19 creates. “It is the cytokine storm that, in turn, kills so many people,” …
CovInnovations™ Rapid RNA Test Can Identify All Strains of COVID-19
CovInnovations™ revealed today that the company’s Rapid RNA COVID-19 test, CovaTest™, is expected to not only detect the presence of COVID-19, but also identify the strain of the disease if it is present. The Rapid RNA test is in the pre-prototype phase of development. If validated, it will be a new non-invasive way of testing …
CovInnovations™ Secures Funding For Covid-19 Related Products
CovInnovations™ has secured $480,000 in funding that will be utilized to accelerate the FDA approval process for CovArrest™, the revolutionary new treatment for hospitalized patients with severe COVID-19 symptoms. The company retained Biotech Research Group, a full service regulatory and product development consulting firm, to help guide the FDA-submission process. BRG has an excellent reputation …
CovInnovations™ Submits Pre-IND, Engages BARDA
Key management personnel from CovInnovations™ attended the Institute for Biomedical Entrepreneurship (IBE) conference in Boston, meeting and making connections with leaders of multiple sectors of the bio tech industry. IBE brings specialized know-how and funding to biomedical researchers and innovators with educational programs and hands-on training that will help them become more aware of how to …
Covinnovations™ Makes Great Strides to Bring CovArrest™ to Market
Throughout the summer, CovInnovations™ made great strides toward bringing its revolutionary COVID-19 treatment, CovArrest™, to market. CovArrest™ already has shown great potential to become the standard of care for those with late-stage COVID-19, thereby alleviating suffering and saving lives around the world. CovInnovations™ has assembled a top-tier team of professionals who are capable of bringing …